Nanexa AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 19
- Market Cap
- -
- Website
- http://nanexa.se
Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D
Phase 1
Recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: NEX-22A, a prolonged release formulation of liraglutide
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Nanexa AB
- Target Recruit Count
- 12
- Registration Number
- NCT06439056
- Locations
- 🇩🇪
Profil, Neuss, Germany
To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Nanexa AB
- Target Recruit Count
- 9
- Registration Number
- NCT05643248
- Locations
- 🇸🇪
CTC Clinical Research Consultants AB, Uppsala, Sweden
Pharmacokinetics, Tolerability and Safety of NEX-18a
Phase 1
Completed
- Conditions
- Myelodysplastic Syndromes (MDS)Chronic Myelomonocytic Leukemia (CMML)Acute Myeloid Leukemia (AML)
- Interventions
- Drug: NEX-18a injection
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Nanexa AB
- Target Recruit Count
- 2
- Registration Number
- NCT05048498
- Locations
- 🇸🇪
Karolinska University Hospital Huddinge, Huddinge, Sweden
🇸🇪Kliniska Forsknings och Utvecklings Enheten KFUE, Uppsala, Sweden
© Copyright 2025. All Rights Reserved by MedPath